FDA approves 4th-generation neurostimulator for fecal incontinence, overactive bladder

The FDA has approved Axonics Inc’s fourth-generation R20 rechargeable sacral neuromodulation system for bladder and bowel dysfunction.According to a company release, the R20 neurostimulator has been labeled for a functional life span of at least 20 years, decreasing the frequency with which patients need to recharge their implanted device to once every 6 to 10 months for 1 hour compared with the third generation’s once a month for 1 hour. Like the Axonics R15, the newer R20 uses the same 5cc form factor and has a similar patient remote control.“Delivering a superior patientRead More

Generated by Feedzy